Stocktoria
REGENTIS BIOMATERIALS LTD. RGNT
REGENTIS BIOMATERIALS LTD. (RGNT) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RGNT | REGENTIS BIOMATERIALS LTD. | 1/9 | — | — | — |
| ISRG | INTUITIVE SURGICAL INC | 6/9 | 12.06 | 50.2 | +20.5% |
| ZBH | ZIMMER BIOMET HOLDINGS, INC. | 5/9 | 3.96 | 24.5 | +7.2% |
| EW | Edwards Lifesciences Corp | 6/9 | 9.6 | 48.7 | +11.5% |
| STE | STERIS plc | 9/9 | 4.5 | 26.9 | +8.7% |
| ALGN | ALIGN TECHNOLOGY INC | 6/9 | 4.56 | 31.1 | +0.9% |
| ENOV | Enovis CORP | 4/9 | -1.51 | — | +6.7% |
About REGENTIS BIOMATERIALS LTD.
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
FAQ
Is RGNT financially healthy?
REGENTIS BIOMATERIALS LTD.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does RGNT pay a dividend?
No, REGENTIS BIOMATERIALS LTD. does not currently pay a dividend.
How profitable is RGNT?
In FY2025, REGENTIS BIOMATERIALS LTD. had a return on equity of -287.7%.
What is the analyst price target for RGNT?
The average Wall-Street price target for REGENTIS BIOMATERIALS LTD. is $10.00, about 405.1% above the recent price, from 1 analysts.
Is RGNT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on REGENTIS BIOMATERIALS LTD.: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.